核苷(酸)类似物间联合用药抗HBV治疗进展

Research progress of combination therapy of nucleos(t) ide analogues in anti-HBV

目前用于慢性乙型肝炎(chronic hepatitis B,CHB)抗病毒治疗的药物有干扰素类(interferons,IFNs)和核苷(酸)类似物(nucleos(t)ide analogues,NAs)两大类。IFNs在抗乙型肝炎病毒(hepatitis B virus,HBV)方面取得了一定的效果,但抗病毒作用有限,且不良反应较大;NAs抗病毒作用强、不良反应发生率低,但也存在一些问题,如停药后易复发、随着疗程延长产生耐药的趋势增加等。本文就近年来国内外对NAs联合用药抗HBV治疗的研究进展作一概述。

Currently,interferons（ IFNs） and nucleos（ t） ide analogues（ NAs） have been used globally in antiviral therapy in chronic hepatitis B（ CHB）. IFNs are limited by lower efficacy and greater adverse reactions,although achieve some results in terms of anti-HBV. NAs exhibit greater antiviral activity,lower incidence rate of adverse reactions,however,some problems exist,such as a high risk of recurrence after these NAs are discontinued and increased resistance rates as treatment prolonged. This review focused on the combination therapy of NAs in anti-HBV.